HIV-1 Vif adaptation to human APOBEC3H haplotypes

Cell Host and Microbe

Volumn 14, Issue 4, 2013, Pages 411-421

  Ooms, Marcel ^a   Brayton, Bonnie ^b   Letko, Michael ^a   Maio, Susan M ^a   Pilcher, Christopher D ^c   Hecht, Frederick M ^c   Barbour, Jason D ^b   Simon, Viviana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS DNA;

ADAPTATION; AMINO ACID SEQUENCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; GENE MUTATION; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADAPTATION, BIOLOGICAL; AMINOHYDROLASES; CELLS, CULTURED; DNA MUTATIONAL ANALYSIS; DNA, VIRAL; HAPLOTYPES; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; PROVIRUSES; REVERSE GENETICS; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; T-LYMPHOCYTES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84886063104     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2013.09.006     Document Type: Article

References (44)

1. J.S. Albin, and R.S. Harris Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics Expert Rev. Mol. Med. 12 2010 e4
2. P. An, G. Bleiber, P. Duggal, G. Nelson, M. May, B. Mangeat, I. Alobwede, D. Trono, D. Vlahov, and S. Donfield APOBEC3G genetic variants and their influence on the progression to AIDS J. Virol. 78 2004 11070 11076
3. P. An, R. Johnson, J. Phair, G.D. Kirk, X.F. Yu, S. Donfield, S. Buchbinder, J.J. Goedert, and C.A. Winkler APOBEC3B deletion and risk of HIV-1 acquisition J. Infect. Dis. 200 2009 1054 1058
4. J.D. Barbour, F.M. Hecht, T. Wrin, M.R. Segal, C.A. Ramstead, T.J. Liegler, M.P. Busch, C.J. Petropoulos, N.S. Hellmann, J.O. Kahn, and R.M. Grant Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection J. Infect. Dis. 190 2004 251 256
5. M. Binka, M. Ooms, M. Steward, and V. Simon The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H J. Virol. 86 2012 49 59
6. T. Bunupuradah, M. Imahashi, T. Iampornsin, K. Matsuoka, Y. Iwatani, T. Puthanakit, J. Ananworanich, J. Sophonphan, A. Mahanontharit, T. Naoe PREDICT Study Team Association of APOBEC3G genotypes and CD4 decline in Thai and Cambodian HIV-infected children with moderate immune deficiency AIDS Res. Ther. 9 2012 34
7. J.L. DeHart, A. Bosque, R.S. Harris, and V. Planelles Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation J. Virol. 82 2008 9265 9272
8. R.C. Edgar MUSCLE: a multiple sequence alignment method with reduced time and space complexity BMC Bioinformatics 5 2004 113
9. R.C. Edgar MUSCLE: multiple sequence alignment with high accuracy and high throughput Nucleic Acids Res. 32 2004 1792 1797
10. P.A. Gourraud, A. Karaouni, J.M. Woo, T. Schmidt, J.R. Oksenberg, F.M. Hecht, T.J. Liegler, and J.D. Barbour APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection Hum. Immunol. 72 2011 207 212
11. T. Haertle, C.J. Carrera, D.B. Wasson, L.C. Sowers, D.D. Richman, and D.A. Carson Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2′,3′-dideoxyadenosine derivatives J. Biol. Chem. 263 1988 5870 5875
12. S. Harada, Y. Koyanagi, and N. Yamamoto Infection of human T-lymphotropic virus type-I (HTLV-I)-bearing MT-4 cells with HTLV-III (AIDS virus): chronological studies of early events Virology 146 1985 272 281
13. A. Harari, M. Ooms, L.C. Mulder, and V. Simon Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H J. Virol. 83 2009 295 303
14. R.S. Harris, K.N. Bishop, A.M. Sheehy, H.M. Craig, S.K. Petersen-Mahrt, I.N. Watt, M.S. Neuberger, and M.H. Malim DNA deamination mediates innate immunity to retroviral infection Cell 113 2003 803 809
15. J.F. Hultquist, J.A. Lengyel, E.W. Refsland, R.S. Larue, L. Lackey, W.L. Brown, and R.S. Harris Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1 J. Virol. 85 2011 11220 11234
16. Y. Iwabu, M. Kinomoto, M. Tatsumi, H. Fujita, M. Shimura, Y. Tanaka, Y. Ishizaka, D. Nolan, S. Mallal, T. Sata, and K. Tokunaga Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes J. Biol. Chem. 285 2010 35350 35358
17. T. Izumi, K. Io, M. Matsui, K. Shirakawa, M. Shinohara, Y. Nagai, M. Kawahara, M. Kobayashi, H. Kondoh, and N. Misawa HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication Proc. Natl. Acad. Sci. USA 107 2010 20798 20803
18. M. Janini, M. Rogers, D.R. Birx, and F.E. McCutchan Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells J. Virol. 75 2001 7973 7986
19. F.A. Koning, E.N. Newman, E.Y. Kim, K.J. Kunstman, S.M. Wolinsky, and M.H. Malim Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets J. Virol. 83 2009 9474 9485
20. B. Korber, and G. Myers Signature pattern analysis: a method for assessing viral sequence relatedness AIDS Res. Hum. Retroviruses 8 1992 1549 1560
21. M.M. Li, L.I. Wu, and M. Emerman The range of human APOBEC3H sensitivity to lentiviral Vif proteins J. Virol. 84 2010 88 95
22. M.T. Liddament, W.L. Brown, A.J. Schumacher, and R.S. Harris APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo Curr. Biol. 14 2004 1385 1391
23. M.H. Malim, and M. Emerman HIV-1 accessory proteins - ensuring viral survival in a hostile environment Cell Host Microbe 3 2008 388 398
24. B. Mangeat, P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts Nature 424 2003 99 103
25. M. Marin, K.M. Rose, S.L. Kozak, and D. Kabat HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation Nat. Med. 9 2003 1398 1403
26. P.J. McLaren, C. Coulonges, S. Ripke, L. van den Berg, S. Buchbinder, M. Carrington, A. Cossarizza, J. Dalmau, S.G. Deeks, and O. Delaneau Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls PLoS Pathog. 9 2013 e1003515
27. M. OhAinle, J.A. Kerns, H.S. Malik, and M. Emerman Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H J. Virol. 80 2006 3853 3862
28. M. OhAinle, J.A. Kerns, M.M. Li, H.S. Malik, and M. Emerman Antiretroelement activity of APOBEC3H was lost twice in recent human evolution Cell Host Microbe 4 2008 249 259
29. M. Ooms, A. Krikoni, A.K. Kress, V. Simon, and C. Münk APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1 J. Virol. 86 2012 6097 6108
30. M. Ooms, M. Letko, M. Binka, and V. Simon The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif PLoS ONE 8 2013 e57744
31. M. Ortiz, N. Guex, E. Patin, O. Martin, I. Xenarios, A. Ciuffi, L. Quintana-Murci, and A. Telenti Evolutionary trajectories of primate genes involved in HIV pathogenesis Mol. Biol. Evol. 26 2009 2865 2875
32. K. Peden, M. Emerman, and L. Montagnier Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI Virology 185 1991 661 672
33. K. Reddy, C.A. Winkler, L. Werner, K. Mlisana, S.S. Abdool Karim, T. Ndung'u CAPRISA Acute Infection Study Team APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load AIDS 24 2010 195 204
34. E.W. Refsland, M.D. Stenglein, K. Shindo, J.S. Albin, W.L. Brown, and R.S. Harris Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction Nucleic Acids Res. 38 2010 4274 4284
35. E.W. Refsland, J.F. Hultquist, and R.S. Harris Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n PLoS Pathog. 8 2012 e1002800
36. P.P. Rose, and B.T. Korber Detecting hypermutations in viral sequences with an emphasis on G → A hypermutation Bioinformatics 16 2000 400 401
37. R.A. Russell, M.D. Moore, W.S. Hu, and V.K. Pathak APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA Retrovirology 6 2009 16
38. A.M. Sheehy, N.C. Gaddis, and M.H. Malim The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif Nat. Med. 9 2003 1404 1407
39. V. Simon, V. Zennou, D. Murray, Y. Huang, D.D. Ho, and P.D. Bieniasz Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification PLoS Pathog. 1 2005 e6
40. L. Tan, P.T.N. Sarkis, T. Wang, C. Tian, and X.-F. Yu Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1 FASEB J. 23 2008 279 287
41. J.P. Vartanian, A. Meyerhans, B. Asjö, and S. Wain-Hobson Selection, recombination, and G - - A hypermutation of human immunodeficiency virus type 1 genomes J. Virol. 65 1991 1779 1788
42. X. Wang, A. Abudu, S. Son, Y. Dang, P.J. Venta, and Y.H. Zheng Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity J. Virol. 85 2011 3142 3152
43. X. Wei, J.M. Decker, H. Liu, Z. Zhang, R.B. Arani, J.M. Kilby, M.S. Saag, X. Wu, G.M. Shaw, and J.C. Kappes Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob. Agents Chemother. 46 2002 1896 1905
44. H. Zhang, B. Yang, R.J. Pomerantz, C. Zhang, S.C. Arunachalam, and L. Gao The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA Nature 424 2003 94 98